Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05970731 · ClinicalTrials.gov registry record · Phase 2
Directed Topical Drug Delivery for Treatment for PASC Hyposmia
A Phase 2 study of Post Acute Sequelae Covid-19 Hyposmia, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05970731 is a Phase 2 study of Post Acute Sequelae Covid-19 Hyposmia that has completed, run by Duke University. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05970731, a Phase 2 study of Post Acute Sequelae Covid-19 Hyposmia, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy of topical intranasal treatment of beclomethasone vs. placebo for improved olfactory function.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Beclomethasone
- DEVICE Microsponge
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-09-05 |
| Est. Completion | 2024-10-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05970731
The ClinicalTrials.gov registry entry for NCT05970731 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post Acute Sequelae Covid-19 Hyposmia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05970731 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05970731 about?
NCT05970731 is a clinical study titled "Directed Topical Drug Delivery for Treatment for PASC Hyposmia". This is a phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy of topical intranasal treatment of beclomethasone vs. placebo for improved olfactory function.
What is the current status of trial NCT05970731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2023-09-05. Estimated completion is 2024-10-07.
What conditions does trial NCT05970731 study?
This clinical trial studies the following conditions: Post Acute Sequelae Covid-19 Hyposmia.
What interventions are being tested in trial NCT05970731?
The interventions under investigation include: Placebo (OTHER), Beclomethasone (DRUG), Microsponge (DEVICE).
Who is sponsoring clinical trial NCT05970731?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05970731 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.